Eucrates Biomedical Acquisition (NASDAQ:EUCR) Trading 0.2% Higher

Eucrates Biomedical Acquisition Corp. (NASDAQ:EUCRGet Rating)’s stock price traded up 0.2% on Monday . The stock traded as high as $9.93 and last traded at $9.92. 993 shares traded hands during mid-day trading, a decline of 95% from the average session volume of 18,874 shares. The stock had previously closed at $9.90.

Eucrates Biomedical Acquisition Stock Up 0.2 %

The company’s fifty day moving average price is $9.98 and its two-hundred day moving average price is $9.94.

Institutional Trading of Eucrates Biomedical Acquisition

Several hedge funds and other institutional investors have recently made changes to their positions in the company. Periscope Capital Inc. boosted its holdings in shares of Eucrates Biomedical Acquisition by 0.8% in the third quarter. Periscope Capital Inc. now owns 178,393 shares of the company’s stock valued at $1,787,000 after acquiring an additional 1,400 shares in the last quarter. UBS Group AG boosted its holdings in Eucrates Biomedical Acquisition by 78.5% during the third quarter. UBS Group AG now owns 3,917 shares of the company’s stock worth $39,000 after buying an additional 1,722 shares in the last quarter. Jane Street Group LLC boosted its holdings in Eucrates Biomedical Acquisition by 2.2% during the third quarter. Jane Street Group LLC now owns 108,553 shares of the company’s stock worth $1,088,000 after buying an additional 2,386 shares in the last quarter. Radcliffe Capital Management L.P. boosted its holdings in Eucrates Biomedical Acquisition by 3.0% during the first quarter. Radcliffe Capital Management L.P. now owns 102,974 shares of the company’s stock worth $1,015,000 after buying an additional 2,974 shares in the last quarter. Finally, Centiva Capital LP boosted its holdings in Eucrates Biomedical Acquisition by 4.9% during the second quarter. Centiva Capital LP now owns 140,393 shares of the company’s stock worth $1,390,000 after buying an additional 6,544 shares in the last quarter. Hedge funds and other institutional investors own 58.22% of the company’s stock.

Eucrates Biomedical Acquisition Company Profile

(Get Rating)

Eucrates Biomedical Acquisition Corp. does not have significant operations. The company intends to effect a merger, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses. It focuses to identify and acquire a business in the biomedical or healthcare-related industries in North America and Europe.

Featured Articles

Receive News & Ratings for Eucrates Biomedical Acquisition Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eucrates Biomedical Acquisition and related companies with MarketBeat.com's FREE daily email newsletter.